HomeSectorLife SciencesAustralia: ENA Respiratory attracts US$22.4m to fund Phase II development of INNA-051...

Australia: ENA Respiratory attracts US$22.4m to fund Phase II development of INNA-051 nasal spray

-

ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, has raised US$22.4m in its Series B financing.  New investment was received from…

Subscription required

This content is for Subscribers only. To access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?
Nick Herbert
Nick Herbert
Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.
Related Articles
More From Author

…

Subscription required

This content is for Subscribers only. To access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?

…

Subscription required

This content is for Subscribers only. To access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?
Advertisement

Related Resources

Related Events